A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Journal Article
| Authors: | Younes, A.; Vose, J. M.; Zelenetz, A. D.; Smith, M. R.; Burris, H. A.; Ansell, S. M.; Klein, J.; Halpern, W.; Miceli, R.; Kumm, E.; Fox, N. L.; Czuczman, M. S. |
| Article Title: | A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma |
| Abstract: | Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL. © 2010 Cancer Research UK. |
| Keywords: | immunohistochemistry; adult; cancer chemotherapy; cancer survival; clinical article; human tissue; treatment response; aged; aged, 80 and over; middle aged; clinical trial; constipation; drug activity; drug tolerability; fatigue; cancer growth; diarrhea; drug efficacy; drug safety; side effect; rituximab; anorexia; progression free survival; apoptosis; liver toxicity; mantle cell lymphoma; multiple cycle treatment; nephrotoxicity; phase 2 clinical trial; anemia; nausea; vomiting; recurrence; herpes zoster; abdominal pain; asthenia; backache; chill; coughing; dizziness; dyspnea; fever; hyperglycemia; pruritus; insomnia; b cell lymphoma; peripheral t cell lymphoma; antibodies, monoclonal; nonhodgkin lymphoma; lymphoma, non-hodgkin; multicenter study; death receptor 4; staining; peripheral edema; limb pain; cancer relapse; open study; hyperbilirubinemia; headache; large cell lymphoma; drug blood level; phase 1 clinical trial; drug half life; dyspepsia; muscle spasm; follicular lymphoma; marginal zone lymphoma; weight bearing; lymphocytoma; upper respiratory tract infection; angioneurotic edema; mapatumumab; drug elimination; face edema; receptors, tnf-related apoptosis-inducing ligand; apo2l; trail; hyperamylasemia; lymph node pain |
| Journal Title: | British Journal of Cancer |
| Volume: | 103 |
| Issue: | 12 |
| ISSN: | 0007-0920 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2010-12-07 |
| Start Page: | 1783 |
| End Page: | 1787 |
| Language: | English |
| DOI: | 10.1038/sj.bjc.6605987 |
| PUBMED: | 21081929 |
| PROVIDER: | scopus |
| PMCID: | PMC3008610 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: BJCAA" - "Source: Scopus" |
